Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C

Expert Opinion on Drug Safety

Volumn 14, Issue 8, 2015, Pages 1317-1326

  Fazel, Yousef ^a   Lam, Brian ^a   Golabi, Pegah ^a   Younossi, Zobair ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Harvoni; ION 4; Ledipasvir; SIRIUS; Sofosbuvir; SOLAR

Indexed keywords

AMIODARONE; INTERFERON; LEDIPASVIR; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; DRUG COMBINATION; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADVERSE OUTCOME; ARTICLE; CHRONIC HEPATITIS C; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; GRAFT RECIPIENT; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; KIDNEY DISEASE; LIVER GRAFT; MULTICENTER STUDY (TOPIC); NAUSEA; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG INTERACTION; HEPATITIS C;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG APPROVAL; DRUG COMBINATIONS; DRUG INTERACTIONS; FLUORENES; HEPATITIS C; HUMANS; URIDINE MONOPHOSPHATE;

EID: 84937243212     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1053868     Document Type: Article

References (35)

1. Metts J, Carmichael L, Kokor W, et al. Hepatitis C: prevalence, transmission, screening, and prevention. FP Essent 2014;427:11-17
2. Smith BD, Morgan RL, Beckett GA, et al. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012;157(11):817-22
3. Ferenci P. Treatment of chronic hepatitis C-are interferons really necessary? Liver Int 2012;32:108-12
4. Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the Ion-1, 2 and 3 clinical trials. Hepatology 2015;61(6):1798-808
5. McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2008;15:475-81
6. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72
7. Marcellin P, Roberts SK, Reddy KR, et al. Safety profile of standard-vs. highdose peginterferon alfa-2a plus standarddose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opin Drug Saf 2012;11:901-9
8. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-5. e2
9. Rose L, Bias TE, Mathias CB, et al. Sofosbuvir: A nucleotide NS5B inhibitor for the treatment of chronic hepatitis C infection. Ann Pharmacother 2014;48(8):1019-29
10. Herbst DA, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013;22:527-36
11. Belema M, Lopez OD, Bender JA, et al. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. J Med Chem 2014;57:1643-72
12. Link JO, Taylor JG, Xu L, et al. Discovery of ledipasvir (GS-5885): A potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem 2014;57:2033-46
13. Pawlotsky J-M. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013;59:375-82
14. Lawitz EJ, Gruener D, Hill JM, et al. A phase 1, randomized, placebocontrolled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012;57:24-31
15. German P, Mathias A, Pang PS, et al. Lack of a clinically significant pharmacokinetic drug-drug interaction between Sofosbuvir (GS-7977) and GS-5885 or GS-9669 in healthy volunteers. Hepatology 2012;56:1072A-3A
16. Soriano V, Labarga P, Barreiro P, et al. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol 2015;11(3):1-9
17. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2015;370:1889-98
18. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and Sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88
19. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93
20. Gilead. Gilead Sciences Inc. (2015). Harvoni (prescribing information); Foster City, California: 2015
21. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixeddose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: An open-label, randomised, phase 3 trial. Lancet Infect Dis 2015;15(6):645-53
22. Gilead. Serious and life threatening cases of symptomatic Bradycardia as well as one case of fatal cardiac arrest reported with coadministration of Amiodarone with either harvoni (ledipasvir and sofosbuvir fixed-dose combination) or with Sovaldi in combination with another direct acting antiviral. 2015
23. Flamm SL GTE, Charlton M, Denning JM, et al. LDV/SOF with Ribavirin for the treatment of HCV in patients with decompansated cirrhosis: preliminary results of a prospective, multicenter study. (SOLAR-1, Cohort A). Hepatology 2014;60:320A
24. Reddy KR, Everson GT, Steven L, et al. Ledipasvir/Sofosbuvir with Ribavirin for the treatment of HCV in patients with post transplant recurence: preliminary results of a prospective, multicenter study (SOLAR-1, Cohort B). Hepatology 2014
25. Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis nonresponsive to previous protease-inhibitor therapy: A randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015;15(4):397-404
26. Osinusi A, Kohli A, Marti MM, et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: An open-label pilot study. Ann Intern Med 2014;161:634-8
27. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015;313:1232-9
28. Naggie S, Cooper C, Saag M, et al. Ledipasvir/Sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1. The Conference of Retroviruses and Opportunistic Infections; 23-26 February 2015; Seattle, WA
29. Gane EJ, Robson RA, Bonacini M, et al. Safety, antiviral efficacy, and pharmacokinetics of Sofosbuvir in patients with severe renal impairment. Hepatology 2014;60:133A
30. Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 2014;46(Suppl 5):S186-96
31. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-65
32. Jody Gilmore KL, Breen D, Trooskin S, et al. Effectiveness of Sofosbuvir/ Simeprevir for HIV/HCV patients in clinical practice. The Conference of Retroviruses and Opportunistic Infections; 23-26 February 2015; Seattle, WA
33. Marks KM, Weinberg EM, Kumar S, et al. Sofosbuvir, Simeprevir, +/-Ribavirin in HCV G1 protease inhibitor experienced patients. The Conference of Retroviruses and Opportunistic Infections; 23-26 February 2015; Seattle, WA
34. Bichoupan K, Tandon N, Yalamanchili R, et al. Branch. Real world cost per SVR with Simeprevir/ Sofosbuvir Ribavirin. The Conference of Retroviruses and Opportunistic Infections; 23-26 February 2015; Seattle, WA
35. Available from: www. hcvguidelines. org